|
|
Candida skin test reagent |
|
Vaxjo ID |
288 |
|
Vaccine Adjuvant Name |
Candida skin test reagent |
|
Alternative Names |
Candin |
|
Adjuvant VO ID |
VO_0005593
|
|
Description |
microorganism derived adjuvant from C. albicans that induces a mixed Th1/Th17 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US |
|
Host Species for Testing |
Human |
|
Components |
extracts from candida albicans - naturally occuring yeast |
|
Appearance |
colorless |
|
Preparation |
two strains of Candida albicans propagated in media containing inorganic salts, biotin, and sucrose, lyophilized and extracted resulting in a clear solution |
|
Function |
innate immune activation |
| References |
Abdallah et al., 2018: Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant. SAGE open medicine. 2018; 6; 2050312118800202. [PubMed: 30245818].
Greenfield et al., 2015: Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015; 4(10); e1031439. [PubMed: 26451301].
Wang et al., 2013: Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013; 31(49); 5806-5813. [PubMed: 24135577].
|
|
